| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.878 | 0.004 | 0.878 | Anticonvulsant | |||
| 0.706 | 0.003 | 0.706 | GABA receptor antagonist | |||
| 0.699 | 0.003 | 0.699 | GABA A receptor antagonist | |||
| 0.667 | 0.002 | 0.667 | Benzodiazepine agonist | |||
| 0.668 | 0.004 | 0.668 | GABA C receptor rho-3 antagonist | 0.207 0.199 DBMET00650 | ||
| 0.637 | 0.003 | 0.637 | GABA receptor agonist | |||
| 0.577 | 0.005 | 0.577 | Anesthetic general | 0.332 0.027 DBMET00650 | ||
| 0.568 | 0.007 | 0.568 | Psychostimulant | 0.28 0.048 DBMET00650 | ||
| 0.458 | 0.012 | 0.458 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.344 | 0.004 | 0.344 | GABA C receptor rho-2 antagonist | |||
| 0.322 | 0.03 | 0.322 | Ca2+/calmodulin-dependent kinase II beta inhibitor | |||
| 0.283 | 0.005 | 0.283 | Potassium channel activator | |||
| 0.38 | 0.119 | 0.38 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.358 | 0.108 | 0.389 | 5 Hydroxytryptamine release inhibitor | 0.389 0.085 DBMET00650 | DBMET00650 | |
| 0.284 | 0.037 | 0.284 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | |||
| 0.234 | 0.002 | 0.234 | Benzodiazepine receptor peripheral-type antagonist | 0.049 0.008 DBMET00650 | ||
| 0.246 | 0.014 | 0.246 | Death-associated protein kinase 2 inhibitor | |||
| 0.218 | 0.009 | 0.218 | Interleukin 8 antagonist | |||
| 0.218 | 0.01 | 0.218 | GABA C receptor antagonist | |||
| 0.25 | 0.049 | 0.25 | RNA-directed DNA polymerase inhibitor | 0.22 0.074 DBMET00650 | ||
| 0.252 | 0.058 | 0.252 | MAP-kinase-activated kinase 5 inhibitor | |||
| 0.197 | 0.006 | 0.197 | Cyclin B3 inhibitor | |||
| 0.264 | 0.073 | 0.264 | Aryl hydrocarbon receptor agonist | |||
| 0.191 | 0.01 | 0.191 | GABA C receptor rho-1 antagonist | |||
| 0.192 | 0.016 | 0.192 | Protein kinase C gamma inhibitor | |||
| 0.186 | 0.013 | 0.186 | Protein kinase C zeta inhibitor | |||
| 0.202 | 0.036 | 0.372 | ATPase inhibitor | 0.372 0.004 DBMET00650 | DBMET00650 | |
| 0.226 | 0.077 | 0.339 | Cyclic AMP phosphodiesterase inhibitor | 0.339 0.029 DBMET00650 | DBMET00650 | |
| 0.165 | 0.019 | 0.328 | Beta glucuronidase inhibitor | 0.328 0.005 DBMET00650 | DBMET00650 | |
| 0.174 | 0.036 | 0.174 | Glutamate receptor antagonist | |||
| 0.155 | 0.018 | 0.155 | Electrolyte absorption antagonist | |||
| 0.146 | 0.008 | 0.174 | Glycine receptor antagonist | 0.174 0.004 DBMET00650 | DBMET00650 | |
| 0.133 | 0.003 | 0.133 | Benzodiazepine antagonist | |||
| 0.206 | 0.079 | 0.206 | Nitric-oxide synthase stimulant | |||
| 0.23 | 0.104 | 0.23 | Gastrin inhibitor | |||
| 0.167 | 0.046 | 0.167 | MAP kinase 3 inhibitor | |||
| 0.142 | 0.03 | 0.142 | Protein kinase C mu inhibitor | |||
| 0.158 | 0.048 | 0.158 | MAP kinase kinase 4 inhibitor | |||
| 0.167 | 0.057 | 0.19 | Lipid peroxidase inhibitor | 0.19 0.046 DBMET00650 | DBMET00650 | |
| 0.17 | 0.06 | 0.17 | Cyclin-dependent kinase 3 inhibitor | |||
| 0.116 | 0.007 | 0.116 | Cholecystokinin antagonist | |||
| 0.212 | 0.106 | 0.212 | DNA damaging | 0.205 0.112 DBMET00650 | ||
| 0.172 | 0.068 | 0.172 | Peroxidase inhibitor | |||
| 0.279 | 0.175 | 0.279 | Calcium channel L-type activator | |||
| 0.108 | 0.013 | 0.108 | NMDA receptor glycine site agonist | |||
| 0.155 | 0.067 | 0.155 | Protein kinase C nu inhibitor | |||
| 0.161 | 0.074 | 0.183 | Interleukin 6 antagonist | 0.183 0.053 DBMET00650 | DBMET00650 | |
| 0.118 | 0.036 | 0.118 | NMDA receptor antagonist | |||
| 0.097 | 0.019 | 0.097 | GABA B receptor agonist | |||
| 0.087 | 0.013 | 0.087 | MDM2 inhibitor | |||
| 0.079 | 0.007 | 0.079 | Purinergic P2X4 antagonist | |||
| 0.081 | 0.01 | 0.081 | Kainate receptor antagonist | |||
| 0.284 | 0.212 | 0.447 | Caspase 9 stimulant | 0.447 0.085 DBMET00650 | DBMET00650 | |
| 0.195 | 0.126 | 0.37 | Interleukin agonist | 0.37 0.024 DBMET00650 | DBMET00650 | |
| 0.088 | 0.021 | 0.088 | Plasminogen activator inhibitor | |||
| 0.112 | 0.044 | 0.161 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.161 0.023 DBMET00650 | DBMET00650 | |
| 0.088 | 0.021 | 0.088 | Protein kinase C beta inhibitor | |||
| 0.103 | 0.037 | 0.103 | Bromodomain-containing protein 2 inhibitor | |||
| 0.079 | 0.015 | 0.079 | Cyclin B2 inhibitor | |||
| 0.087 | 0.025 | 0.087 | NMDA receptor agonist | |||
| 0.078 | 0.018 | 0.078 | AMPA receptor antagonist | |||
| 0.082 | 0.023 | 0.082 | Protein kinase C eta inhibitor | |||
| 0.161 | 0.102 | 0.161 | Ca2+/calmodulin-dependent protein kinase inhibitor | |||
| 0.116 | 0.059 | 0.116 | 5 Hydroxytryptamine 3A agonist | |||
| 0.079 | 0.023 | 0.079 | Cyclin B1 inhibitor | |||
| 0.073 | 0.019 | 0.073 | Cyclin B inhibitor | |||
| 0.061 | 0.008 | 0.061 | Cholecystokinin B antagonist | |||
| 0.106 | 0.053 | 0.106 | Creatine kinase inhibitor | |||
| 0.175 | 0.124 | 0.175 | ErbB-1 antagonist | |||
| 0.086 | 0.036 | 0.086 | Protein kinase B beta inhibitor | |||
| 0.204 | 0.155 | 0.204 | Ca2+/calmodulin-dependent kinase IV inhibitor | |||
| 0.066 | 0.022 | 0.129 | Phosphorylase inhibitor | 0.129 0.009 DBMET00650 | DBMET00650 | |
| 0.178 | 0.134 | 0.43 | Antioxidant | 0.43 0.03 DBMET00650 | DBMET00650 | |
| 0.094 | 0.051 | 0.203 | NADH dehydrogenase inhibitor | 0.203 0.01 DBMET00650 | DBMET00650 | |
| 0.123 | 0.082 | 0.123 | Ca2+/calmodulin-dependent kinase II delta inhibitor | |||
| 0.181 | 0.139 | 0.181 | 5 Hydroxytryptamine release stimulant | |||
| 0.151 | 0.11 | 0.151 | Succinate dehydrogenase inhibitor | |||
| 0.108 | 0.068 | 0.109 | Cystathionine beta-synthase inhibitor | 0.109 0.067 DBMET00650 | DBMET00650 | |
| 0.096 | 0.059 | 0.096 | Potassium channel (Ca-activated) activator | |||
| 0.053 | 0.017 | 0.053 | GABA B receptor antagonist | |||
| 0.126 | 0.091 | 0.237 | Cell wall synthesis inhibitor | 0.237 0.019 DBMET00650 | DBMET00650 | |
| 0.233 | 0.199 | 0.233 | Analgesic | |||
| 0.096 | 0.062 | 0.096 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.038 | 0.005 | 0.038 | 1,3-Beta-glucan synthase inhibitor | 0.032 0.011 DBMET00650 | ||
| 0.041 | 0.008 | 0.041 | NMDA receptor glycine site antagonist | |||
| 0.147 | 0.114 | 0.147 | Catenin beta inhibitor | |||
| 0.161 | 0.129 | 0.161 | Aldehyde oxidase inhibitor | |||
| 0.047 | 0.018 | 0.047 | Kainate receptor 2 antagonist | |||
| 0.188 | 0.159 | 0.188 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.097 | 0.07 | 0.097 | Nav1.1 sodium channel blocker | |||
| 0.099 | 0.072 | 0.099 | Ferrochelatase inhibitor | |||
| 0.109 | 0.084 | 0.109 | MAP kinase 12 inhibitor | |||
| 0.192 | 0.168 | 0.192 | 5 Hydroxytryptamine uptake stimulant | |||
| 0.038 | 0.013 | 0.038 | Cyclin E2 inhibitor | |||
| 0.078 | 0.053 | 0.078 | MAP kinase kinase 7 inhibitor | |||
| 0.126 | 0.102 | 0.126 | MAP3K9 inhibitor | |||
| 0.049 | 0.026 | 0.049 | NMDA receptor subunit 3B antagonist | |||
| 0.049 | 0.027 | 0.049 | Benzodiazepine inverse agonist | |||
| 0.124 | 0.101 | 0.124 | Death-associated protein kinase 1 inhibitor | |||
| 0.122 | 0.1 | 0.122 | Aurora-C kinase inhibitor | |||
| 0.082 | 0.061 | 0.082 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | |||
| 0.142 | 0.122 | 0.142 | Neurotensin receptor agonist | |||
| 0.037 | 0.019 | 0.037 | Factor XI inhibitor | |||
| 0.063 | 0.046 | 0.063 | Kallikrein 7 inhibitor | |||
| 0.042 | 0.025 | 0.042 | Acid-sensing ion channel blocker | |||
| 0.098 | 0.084 | 0.098 | MAP kinase 13 inhibitor | |||
| 0.081 | 0.067 | 0.081 | D-Ala-D-Ala ligase inhibitor | |||
| 0.104 | 0.09 | 0.104 | Sphingosine 1-phosphate receptor 2 agonist | |||
| 0.048 | 0.037 | 0.048 | Bromodomain-containing protein 3 inhibitor | |||
| 0.094 | 0.086 | 0.094 | Nav1.4 sodium channel blocker | |||
| 0.073 | 0.065 | 0.073 | Chymotrypsin inhibitor | |||
| 0.056 | 0.05 | 0.056 | Cyclin D1 inhibitor | |||
| 0.129 | 0.124 | 0.135 | Ca2+-transporting ATPase inhibitor | 0.135 0.096 DBMET00650 | DBMET00650 | |
| 0.041 | 0.036 | 0.041 | Alpha 1L adrenoreceptor agonist | |||
| 0.127 | 0.124 | 0.127 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | |||
| 0.066 | 0.063 | 0.066 | Phospholipase D inhibitor | |||
| 0.061 | 0.058 | 0.061 | Potassium channel large-conductance Ca-activated activator | |||
| 0.036 | 0.034 | 0.036 | AMPA 4 receptor antagonist | |||
| 0.024 | 0.023 | 0.024 | Thymidine phosphorylase inhibitor | |||
| 0.226 | 0.225 | 0.226 | MAP kinase kinase 6 inhibitor | |||
| 0.028 | 0.028 | 0.101 | Trypsin I inhibitor | 0.101 0.006 DBMET00650 | DBMET00650 | |
| 0.057 | 0.058 | 0.107 | Trypsin inhibitor | 0.107 0.014 DBMET00650 | DBMET00650 | |
| 0.02 | 0.023 | 0.022 | Kainate receptor 4 antagonist | 0.022 0.02 DBMET00650 | DBMET00650 | |
| 0.143 | 0.149 | 0.163 | Neurotrophic factor enhancer | 0.163 0.119 DBMET00650 | DBMET00650 | |
| 0.081 | 0.087 | 0.189 | UDP-glucose 4-epimerase inhibitor | 0.189 0.02 DBMET00650 | DBMET00650 | |
| 0.045 | 0.058 | 0.082 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.082 0.019 DBMET00650 | DBMET00650 | |
| 0.011 | 0.045 | 0.016 | O6-alkylguanine-DNA alkyltransferase inhibitor | 0.016 0.014 DBMET00650 | DBMET00650 | |
| 0.017 | 0.054 | 0.107 | Factor X inhibitor | 0.107 0.01 DBMET00650 | DBMET00650 | |
| 0.02 | 0.058 | 0.029 | Toll-Like receptor 4 agonist | 0.029 0.012 DBMET00650 | DBMET00650 | |
| 0.085 | 0.124 | 0.113 | Photosensitizer | 0.113 0.066 DBMET00650 | DBMET00650 | |
| 0.153 | 0.197 | 0.266 | DNA synthesis inhibitor | 0.266 0.057 DBMET00650 | DBMET00650 | |
| 0.105 | 0.154 | 0.25 | Hemostatic | 0.25 0.022 DBMET00650 | DBMET00650 | |
| 0.18 | 0.229 | 0.394 | Histamine release inhibitor | 0.394 0.079 DBMET00650 | DBMET00650 | |
| 0.054 | 0.105 | 0.074 | Glycine receptor agonist | 0.074 0.047 DBMET00650 | DBMET00650 | |
| 0.096 | 0.157 | 0.209 | Mannose-6-phosphate isomerase inhibitor | 0.209 0.026 DBMET00650 | DBMET00650 | |
| 0.066 | 0.133 | 0.133 | DNA intercalator | 0.133 0.051 DBMET00650 | DBMET00650 | |
| 0.082 | 0.152 | 0.114 | Alkaline phosphatase inhibitor | 0.114 0.094 DBMET00650 | DBMET00650 | |
| 0.056 | 0.127 | 0.233 | Topoisomerase I inhibitor | 0.233 0.019 DBMET00650 | DBMET00650 | |
| 0.092 | 0.164 | 0.166 | DNA repair enzyme inhibitor | 0.166 0.019 DBMET00650 | DBMET00650 | |
| 0.085 | 0.177 | 0.137 | Diuretic | 0.137 0.088 DBMET00650 | DBMET00650 | |
| 0.012 | 0.106 | 0.046 | Sodium/glucose cotransporter inhibitor | 0.046 0.006 DBMET00650 | DBMET00650 | |
| 0.069 | 0.167 | 0.153 | Alpha-N-acetylglucosaminidase inhibitor | 0.153 0.053 DBMET00650 | DBMET00650 | |
| 0.051 | 0.178 | 0.094 | Triose-phosphate isomerase inhibitor | 0.094 0.054 DBMET00650 | DBMET00650 | |
| 0.024 | 0.152 | 0.106 | Antineoplastic antibiotic | 0.106 0.043 DBMET00650 | DBMET00650 | |
| 0.048 | 0.184 | 0.099 | ATPase (Vacuolar H+) inhibitor | 0.099 0.041 DBMET00650 | DBMET00650 | |
| 0.054 | 0.195 | 0.208 | Amylase inhibitor | 0.208 0.041 DBMET00650 | DBMET00650 | |
| 0.055 | 0.196 | 0.158 | AMP-activated protein kinase stimulant | 0.158 0.023 DBMET00650 | DBMET00650 | |
| 0.036 | 0.179 | 0.061 | Adenine nucleotide translocase inhibitor | 0.061 0.026 DBMET00650 | DBMET00650 | |
| 0.026 | 0.174 | 0.081 | Heparanase inhibitor | 0.081 0.006 DBMET00650 | DBMET00650 | |
| 0.078 | 0.225 | 0.222 | Hexokinase inhibitor | 0.222 0.025 DBMET00650 | DBMET00650 | |
| 0.124 | 0.273 | 0.411 | Cholesterol antagonist | 0.411 0.047 DBMET00650 | DBMET00650 | |
| 0.007 | 0.158 | 0.047 | Sodium/glucose cotransporter 2 inhibitor | 0.047 0.007 DBMET00650 | DBMET00650 | |
| 0.019 | 0.175 | 0.086 | Protein 50S ribosomal subunit inhibitor | 0.086 0.017 DBMET00650 | DBMET00650 | |
| 0.03 | 0.187 | 0.131 | Topoisomerase II alpha inhibitor | 0.131 0.027 DBMET00650 | DBMET00650 | |
| 0.06 | 0.218 | 0.09 | Glutamate release inhibitor | 0.09 0.062 DBMET00650 | DBMET00650 | |
| 0.141 | 0.303 | 0.294 | Caspase 3 stimulant | 0.294 0.082 DBMET00650 | DBMET00650 | |
| 0.019 | 0.188 | 0.077 | Phosphofructokinase-1 inhibitor | 0.077 0.043 DBMET00650 | DBMET00650 | |
| 0.12 | 0.306 | 0.364 | Peptidyltransferase inhibitor | 0.364 0.01 DBMET00650 | DBMET00650 | |
| 0.079 | 0.28 | 0.265 | Non-steroidal antiinflammatory agent | 0.265 0.037 DBMET00650 | DBMET00650 | |
| 0.123 | 0.348 | 0.333 | Apoptosis antagonist | 0.333 0.065 DBMET00650 | DBMET00650 | |
| 0.13 | 0.358 | 0.364 | Interleukin 2 agonist | 0.364 0.04 DBMET00650 | DBMET00650 | |
| 0.066 | 0.304 | 0.211 | NOS3 expression enhancer | 0.211 0.037 DBMET00650 | DBMET00650 | |
| 0.113 | 0.369 | 0.518 | Antibacterial | 0.518 0.036 DBMET00650 | DBMET00650 | |
| 0.065 | 0.321 | 0.373 | Free radical scavenger | 0.373 0.034 DBMET00650 | DBMET00650 | |
| 0.007 | 0.278 | 0.03 | Protein 30S ribosomal subunit inhibitor | 0.03 0.013 DBMET00650 | DBMET00650 | |
| 0.046 | 0.318 | 0.175 | Cyclooxygenase 3 inhibitor | 0.175 0.03 DBMET00650 | DBMET00650 | |
| 0.055 | 0.333 | 0.353 | Immunostimulant | 0.353 0.063 DBMET00650 | DBMET00650 | |
| 0.021 | 0.302 | 0.063 | Factor IXa inhibitor | 0.063 0.024 DBMET00650 | DBMET00650 | |
| 0.037 | 0.335 | 0.112 | DNA polymerase I inhibitor | 0.112 0.074 DBMET00650 | DBMET00650 | |
| 0.091 | 0.391 | 0.139 | CC chemokine 6 receptor antagonist | 0.139 0.043 DBMET00650 | DBMET00650 | |
| 0.052 | 0.361 | 0.16 | DNA methyltransferase I inhibitor | 0.16 0.094 DBMET00650 | DBMET00650 | |
| 0.032 | 0.341 | 0.059 | Lipocortins synthesis agonist | 0.059 0.039 DBMET00650 | DBMET00650 | |
| 0.081 | 0.397 | 0.401 | Antithrombotic | 0.401 0.049 DBMET00650 | DBMET00650 | |
| 0.037 | 0.373 | 0.132 | Anticoagulant | 0.132 0.097 DBMET00650 | DBMET00650 | |
| 0.073 | 0.413 | 0.189 | Hypoxia-inducible factor 1 alpha inhibitor | 0.189 0.165 DBMET00650 | DBMET00650 | |
| 0.059 | 0.408 | 0.129 | Interferon gamma antagonist | 0.129 0.113 DBMET00650 | DBMET00650 | |
| 0.048 | 0.405 | 0.176 | DNA methylase inhibitor | 0.176 0.096 DBMET00650 | DBMET00650 | |
| 0.022 | 0.385 | 0.186 | Topoisomerase II inhibitor | 0.186 0.036 DBMET00650 | DBMET00650 | |
| 0.042 | 0.45 | 0.166 | Vasodilator | 0.166 0.136 DBMET00650 | DBMET00650 | |
| 0.023 | 0.439 | 0.098 | Uric acid excretion stimulant | 0.098 0.055 DBMET00650 | DBMET00650 | |
| 0.053 | 0.474 | 0.324 | Transcription factor NF kappa B inhibitor | 0.324 0.085 DBMET00650 | DBMET00650 | |
| 0.015 | 0.454 | 0.063 | Glucose-6-phosphate translocase inhibitor | 0.063 0.02 DBMET00650 | DBMET00650 | |
| 0.082 | 0.528 | 0.384 | Apoptosis agonist | 0.384 0.122 DBMET00650 | DBMET00650 | |
| 0.028 | 0.5 | 0.132 | Toll-Like receptor 4 antagonist | 0.132 0.033 DBMET00650 | DBMET00650 | |
| 0.012 | 0.487 | 0.063 | Antibiotic Aminoglycoside-like | 0.063 0.008 DBMET00650 | DBMET00650 | |
| 0.018 | 0.496 | 0.268 | Acetylcholinesterase inhibitor | 0.268 0.017 DBMET00650 | DBMET00650 | |
| 0.006 | 0.543 | 0.281 | Selectin antagonist | 0.281 0.006 DBMET00650 | DBMET00650 | |
| 0.049 | 0.586 | 0.312 | Immunomodulator | 0.312 0.076 DBMET00650 | DBMET00650 | |
| 0.038 | 0.579 | 0.368 | Immunosuppressant | 0.368 0.077 DBMET00650 | DBMET00650 | |
| 0.027 | 0.583 | 0.23 | Nitric oxide antagonist | 0.23 0.057 DBMET00650 | DBMET00650 | |
| 0.017 | 0.624 | 0.464 | Angiogenesis stimulant | 0.464 0.014 DBMET00650 | DBMET00650 | |
| 0.024 | 0.648 | 0.319 | Platelet adhesion inhibitor | 0.319 0.028 DBMET00650 | DBMET00650 | |
| 0.02 | 0.645 | 0.145 | Insulin secretagoues | 0.145 0.08 DBMET00650 | DBMET00650 | |
| 0.045 | 0.704 | 0.476 | Antiinflammatory | 0.476 0.098 DBMET00650 | DBMET00650 | |
| 0.012 | 0.681 | 0.22 | Cholinergic | 0.22 0.038 DBMET00650 | DBMET00650 | |
| 0.026 | 0.705 | 0.102 | Transcription factor NF kappa B stimulant | 0.102 0.037 DBMET00650 | DBMET00650 | |
| 0.027 | 0.742 | 0.308 | Hepatoprotectant | 0.308 0.027 DBMET00650 | DBMET00650 | |
| 0.014 | 0.753 | 0.182 | Tumour necrosis factor alpha release inhibitor | 0.182 0.125 DBMET00650 | DBMET00650 | |
| 0.01 | 0.752 | 0.184 | Thrombolytic | 0.184 0.06 DBMET00650 | DBMET00650 | |
| 0.011 | 0.776 | 0.118 | Cell adhesion inhibitor | 0.118 0.067 DBMET00650 | DBMET00650 | |
| 0.02 | 0.791 | 0.394 | Hypoglycemic | 0.394 0.029 DBMET00650 | DBMET00650 | |
| 0.005 | 0.957 | 0.38 | Cyclophilin D inhibitor | 0.38 0.102 DBMET00650 | DBMET00650 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |